tiprankstipranks
Careteq Ltd. (AU:CTQ)
ASX:CTQ
Australian Market
Want to see AU:CTQ full AI Analyst Report?

Careteq Ltd. (CTQ) AI Stock Analysis

1 Followers

Top Page

AU:CTQ

Careteq Ltd.

(Sydney:CTQ)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - Gpt-5.6Sol)
Rating:46Neutral
Price Target:
AU$0.01
▲(30.00% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by financial performance—persistent net losses and consistently negative operating/free cash flow outweigh the benefits of strong recent revenue growth and improved (very low) leverage. Technicals are only mildly supportive with mixed momentum, and valuation is pressured by a negative P/E with no dividend yield provided.
Positive Factors
Strong Revenue Traction
The substantial 2026 revenue step-up indicates that Careteq is achieving stronger commercial traction and expanding its business base. If this growth persists, greater scale could improve operating leverage, support investment in the platform, and strengthen its position in healthcare information services over the next several quarters.
Negative Factors
Persistent Net Losses
Persistent net losses show that Careteq has not yet converted its growing revenue base into sustainable profitability. Continued operating losses can constrain reinvestment, increase dependence on external funding, and make it harder to demonstrate that recent commercial growth will translate into durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Traction
The substantial 2026 revenue step-up indicates that Careteq is achieving stronger commercial traction and expanding its business base. If this growth persists, greater scale could improve operating leverage, support investment in the platform, and strengthen its position in healthcare information services over the next several quarters.
Read all positive factors

Careteq Ltd. (CTQ) vs. iShares MSCI Australia ETF (EWA)

Careteq Ltd. Business Overview & Revenue Model

Company Description
Careteq Limited engages in medication management and clinical governance for health, aged, and home care sectors in Australia. The company provides healthcare safety and clinical services. Careteq Limited was incorporated in 2016 and is based in M...

Careteq Ltd. Financial Statement Overview

Summary
Revenue growth improved markedly (notably the strong step-up into 2026), and leverage is now very low relative to equity, reducing balance-sheet risk. However, net losses persist, profitability is inconsistent with highly volatile gross margins, and operating/free cash flow remain negative across all years provided—keeping overall financial strength below average.
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
33
Negative
BreakdownJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue6.08M7.62M7.23M4.98M4.43M
Gross Profit5.79M1.50M6.74M-2.44M4.14M
EBITDA13.95K275.62K-826.62K-2.65M-5.90M
Net Income-398.12K-72.20K-2.67M-4.33M-5.25M
Balance Sheet
Total Assets3.78M5.94M6.82M7.57M8.02M
Cash, Cash Equivalents and Short-Term Investments3.19M1.05M1.25M1.85M4.50M
Total Debt47.56K2.37M192.98K961.96K0.00
Total Liabilities549.17K4.42M3.30M4.02M1.72M
Stockholders Equity3.23M1.52M1.97M2.14M6.30M
Cash Flow
Free Cash Flow-1.56M-804.93K-2.59M-3.42M-4.54M
Operating Cash Flow-1.50M-732.06K-1.30M-2.53M-4.52M
Investing Cash Flow3.92M119.16K-570.80K-799.63K-256.83K
Financing Cash Flow-278.85K400.96K1.27M687.55K8.81M

Careteq Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.01
Negative
200DMA
Market Momentum
MACD
>-0.01
Negative
RSI
46.30
Neutral
STOCH
-50.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.30 is Neutral, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTQ.

Careteq Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
AU$141.73M61.762.53%26.61%41.67%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$163.64M-9.45-203.69%-1.53%28.29%
50
Neutral
AU$18.60M-578.72%113.42%29.17%
49
Neutral
AU$35.44M-1.91-58.13%2.08%-195.31%
46
Neutral
AU$9.53M-10.8311.00%-20.21%-66.67%
43
Neutral
AU$22.99M-2.53-1688.04%11.45%0.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CTQ
Careteq Ltd.
0.01
<0.01
8.33%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.20
-0.04
-17.02%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.11
-47.83%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
AU:ICR
InteliCare Holdings Limited
0.03
<0.01
52.94%
AU:PCK
PainChek Ltd
0.11
-0.33
-75.00%

Careteq Ltd. Corporate Events

ReNerve Outlines 2026 Governance Framework Aligned with ASX Principles
Aug 27, 2026
ReNerve Limited has reaffirmed its adherence to the ASX Corporate Governance Principles and Recommendations in its 2026 corporate governance statement, detailing the board&#8217;s responsibility for strategy, risk management, and shareholder accou...
Careteq Files Updated Corporate Governance Statement with ASX
Aug 27, 2026
Careteq Limited has lodged its Corporate Governance Statement for the year ended 30 June 2026 with the ASX, confirming it is current as at 27 August 2026 and accessible via the company&#8217;s investor centre website. The filing complies with ASX ...
Careteq Resets Balance Sheet and Doubles Down on HMR Referrals Platform
Aug 27, 2026
Careteq has completed a major balance sheet and strategic reset in FY26, divesting its Embedded Health Solutions business, repaying all borrowings, raising $2.2 million in new equity and converting all convertible notes into shares. The company fi...
Careteq books deeper loss as subsidiary sale reshapes balance sheet
Aug 27, 2026
Careteq Limited reported a 21.3% fall in revenues to $6.08 million for the year to June 30, 2026, and a sharply higher after-tax loss of $398,121, with no dividends declared. Despite the weaker operating performance, net tangible assets per share ...
Careteq forms Advisory Board to drive HMR Referrals and AI growth
Aug 3, 2026
Careteq has established a new Advisory Board to accelerate growth of its HMR Referrals business and sharpen its artificial intelligence strategy, as it concentrates capital and management attention on this core platform. The board will advise on c...
Careteq Options Lapse, Trimming Potential Future Dilution
Aug 2, 2026
Careteq Ltd., listed on the ASX under the code CTQ, operates in the technology-enabled care and health services sector, using equity and options within its capital structure to support growth and align interests with investors and other stakeholde...
Careteq strengthens balance sheet and pivots to HMR Referrals platform
Jul 30, 2026
Careteq has completed a transformational June quarter, divesting Embedded Health Solutions, executing a two-tranche capital raising, and repaying all borrowings, which collectively lifted its cash balance to $3.2 million and removed all debt and c...
Careteq secures ASX backing as it pivots to HMR Referrals growth
Jul 22, 2026
Careteq has secured continued quotation of its securities on the ASX after the exchange confirmed the company retains sufficient operations and financial strength following the sale of its Embedded Health Solutions subsidiary. The confirmation sta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2026